Indian pharma remains a long-term opportunity despite US tariff concerns, says Srinivas Rao Ravuri, Chief Investment Officer at Bajaj Life Insurance. He prefers contract manufacturers over generic drugmakers, backs the quick commerce leader despite rich valuations, and sees tactical opportunities in IT. Watch his investment thesis.
